| Code | CSB-RA004936MB16HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to mitazalimab, targeting CD40, a costimulatory receptor belonging to the tumor necrosis factor receptor superfamily. CD40 is expressed on antigen-presenting cells, B cells, and various non-immune cells, playing a crucial role in adaptive immunity by regulating T cell priming, B cell activation, and inflammatory responses. Through CD40-CD40L interactions, this pathway influences immune cell differentiation, antibody production, and cytokine secretion. Dysregulation of CD40 signaling is implicated in autoimmune disorders, inflammatory diseases, and cancer, where it can modulate tumor immunity and the immunosuppressive microenvironment.
Mitazalimab is an agonistic anti-CD40 antibody originally developed to enhance antitumor immune responses by activating dendritic cells and promoting T cell-mediated immunity. This biosimilar provides researchers with a valuable tool for investigating CD40-mediated immune activation, studying mechanisms of immune checkpoint modulation, exploring combination immunotherapy strategies, and evaluating CD40 pathway involvement in oncology and autoimmune disease models.
There are currently no reviews for this product.